Alzprotect Receives FDA Clearance for AZP2006 in Progressive Supranuclear Palsy
Key Insights
Alzprotect (search) announced FDA clearance of its Investigational New Drug application for AZP2006 (Ezeprogind®) to treat Progressive Supranuclear Palsy (search), enabling U.S. clinical development.
The IND clearance supports Alzprotect (search)'s planned participation in the NIH/NIA (search)-funded Progressive Supranuclear Palsy (search) Trial Platform, where AZP2006 was selected as one of the first candidates for evaluation.
AZP2006 is an oral small molecule designed to restore lysosomal homeostasis by modulating the Progranulin/Prosaposin (search) pathway, targeting core neurodegeneration mechanisms rather than symptoms.
French biotechnology company Alzprotect (search) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (search) (PSP (search)). The regulatory milestone enables the company to initiate clinical development of its experimental therapy in the United States for a rare neurodegenerative disease that currently has no approved disease-modifying treatments.
Regulatory Pathway Alignment
"FDA IND clearance is a pivotal step in our PSP (search) program," said Philippe Verwaerde, PhD, President & Chief Science Officer. "We can now expand our clinical efforts in the U.S. to evaluate AZP2006's potential to address PSP, a severe neurodegenerative disease with no approved disease-modifying therapies."
Dr. Artin Karapet, Chief Medical Officer, emphasized the strategic importance of the clearance: "The FDA's clearance of our IND for AZP2006 is a pivotal milestone, aligning U.S. and European regulatory pathways and enabling the initiation of rigorous clinical trials in the United States for patients living with PSP (search)."
NIH Trial Platform Participation
The IND clearance supports Alzprotect (search)'s planned participation in the NIH/NIA (search)-funded Progressive Supranuclear Palsy (search) Trial Platform (PTP). AZP2006 was selected as one of the first candidates for evaluation in the PTP, reinforcing the relevance of Alzprotect's lysosomal dysfunction approach in treating PSP (search).
Novel Mechanism of Action
AZP2006 represents an innovative approach to neurodegenerative disease treatment as a small oral molecule designed to restore lysosomal homeostasis by modulating the Progranulin/Prosaposin (search) pathway. This mechanism targets core mechanisms of neurodegeneration rather than addressing symptoms alone, potentially offering disease-modifying benefits for patients with PSP (search).
The drug has received Orphan Drug Designation in both Europe and the United States for PSP (search), reflecting its potential to address significant unmet medical need. Clinical data from Phase 1 and Phase 2a studies have demonstrated a favorable safety profile and promising clinical signals.
Disease Background and Unmet Need
Progressive Supranuclear Palsy (search) is a rare, rapidly progressive tauopathy (search) characterized by postural instability, falls, ocular motor dysfunction, and cognitive impairment. The disease represents a significant challenge for patients and healthcare providers, as there are currently no approved disease-modifying treatments available in the United States.
Development Strategy
Alzprotect (search) plans to advance AZP2006 into a randomized Phase 2b proof-of-concept trial in PSP (search). The company's development strategy includes potential expansion into other neurodegenerative diseases, including Parkinson's disease (search), Alzheimer's disease (search), and amyotrophic lateral sclerosis (ALS (search)).
Founded in 2007 in Lille, France, Alzprotect (search) develops innovative therapies aimed at slowing or halting neurodegenerative diseases and restoring brain function. The company is supported by BPIfrance, the French National Research Agency, and Eurasanté, with its portfolio protected by four international patent families.